Accueil   Diary - News   All news Adocia reports positive results

Adocia reports positive results

Adocia announced positive results from a Phase IIa clinical trial evaluating its innovative fast-acting formulation of recombinant human insulin, HinsBet, in comparison to Eli Lilly’s commercial products, Humalog® (insulin lispro) and Humulin® (recombinant human insulin). Adocia’s HinsBet formulation incorporates proprietary BioChaperone® technology which enables accelerated absorption of prandial insulins. Annual revenues for Humulin and Humalog, both off-patent, are USD 1.4 B and USD 2.8 B1 respectively.

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree